Solvonis Therapeutics (LSE:SVNS) has released unaudited interim results for the six months to 30 June 2026, reporting a slightly narrower loss, lower cash and net assets, pipeline progress in addiction and PTSD programmes, and a £1.3 million placing completed after the period end.

What Solvonis Therapeutics announced

In an announcement on 30 September 2026, the London Stock Exchange-listed drug developer reported a loss before taxation of £1,437,000 for the half year, compared with £1,621,000 in the first half of 2025. Cash and cash equivalents at 30 June 2026 were £659,000, down from £1,719,000 a year earlier.

Non-Executive Chairman Dennis Purcell said that in the first half of 2026 Solvonis had advanced its clinical and discovery programmes, added to its intellectual property portfolio and sharpened its strategy for delivering Shareholder value.

Pipeline developments behind the update

The company's lead programme is SVN-001 for severe Alcohol Use Disorder. The Chairman's statement said that in April the Board confirmed its intention to prioritise advancement through completion of Phase 3, reflecting its belief that successful results could create substantially greater value and improve its position in future strategic discussions.

For SVN-002, the company said: "In June, positive preclinical bridging data marked an important step forward for SVN-002, our esketamine oral thin-film programme for moderate-to-severe Alcohol Use Disorder in the United States."

SVN-114 was selected as the lead candidate in the PTSD programme, where the company said two U.S. composition-of-matter patents covering distinct chemical series had added to the programme's broader intellectual property estate. SVN-015 has been expanded into depression and is being evaluated in stimulant use disorder with funding from the US National Institute on Drug Abuse (NIDA).

Financial context and the post-period placing

Net Assets were £4,810,000 at 30 June 2026, compared with £6,935,000 a year earlier, while total assets were £6,427,000 against £9,545,000. The group recorded a net cash outflow from operations of £1,067,000, compared with an inflow of £966,000 in the first half of 2025. The Balance Sheet showed a retained Deficit of £17,732,000.

After the period end, in August 2026, Solvonis completed a £1.3 million placing of 1,083,333,333 shares at £0.0012 each. It also issued 10,000,000 shares in lieu of fees and 133,333,333 warrants exercisable over five years at £0.0012. Following the fundraise, the directors said "the Group now has sufficient Working Capital to execute its operations over the next 12 months. Accordingly, the Directors believe that the Group will be able to continue as a going concern."

Risks for shareholders to consider

The figures show a smaller cash balance at the half-year mark and a large number of new shares issued at a low price after it, which has increased the share count. Solvonis's value depends heavily on clinical and regulatory outcomes, particularly the Phase 3 progress of SVN-001, and the working capital statement covers a 12-month horizon. Like many early-stage LSE stocks in biotechnology, the group may need further funding to reach later milestones.

What investors may watch next

Other post-period items include the selection of SVN-015 by NIDA for additional funded preclinical evaluation, a European composition-of-matter Patent allowance for the PTSD programme in September and the appointment of a new corporate broker. Updates on SVN-001's Phase 3 path and SVN-002's move towards US clinical development are likely to be closely followed.

Solvonis sets out its priorities

Purcell summarised the strategy: "Our priorities remain clear: advance SVN-001 towards its Phase 3 outcome, progress SVN-002 towards U.S. clinical development and build the value of our proprietary programmes through targeted investment. Disciplined capital allocation remains central to our approach." For those tracking healthcare names on the UK stock market, the interims set clinical progress against a tight capital position.